Barif®

Febuxostat
Anti-gout (Anti-gout Preparations)

Indication:

Barif^TM is indicated for the chronic management of hyperuricemia in patients with gout. Barif^TM is not recommended for the treatment of asymptomatic hyperuricemia.

Dosage & Administration:

Barif^TM is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Barif is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, Barif^TM 80 mg is recommended.

Barif^TM can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febuxostat to patients with mild to moderate renal or hepatic impairment.

Preparation:

Barif^TM: Each box contains 30 tablets.